Coriell Institute for Medical Research investigators and their colleagues have launched a study to examine the influence of genetics on opioid addiction and abuse, the Philadelphia-area public …Read More
News from the network
A new drug to treat spinal muscular atrophy (SMA) approved by the Food and Drug Administration (FDA) on Friday will come with a price tag of $2.1 …Read More
In November 2018, Chinese biophysics researcher He Jiankui shocked the world with the announcement that he had created the world’s first gene-edited infants. A storm of condemnation …Read More
The search for a matching stem cell donor becomes exponentially more difficult if you are a member of an ethnic minority — and especially if you’re mixed …Read More
The CRISPR-Cas9 gene editing system has been hailed as a promising solution to a range of genetic diseases, but the technology has proven difficult to deliver into …Read More
News from RSSPQ
The next board of directors’ meeting of the QNPHC will be held on July 5th.
David Levine, Chairman of the Board of Directors of the Quebec Network for Personalized Health Care (QNPHC) is pleased to announce the appointment of Michelle Savoie as Chief Executive of the QNPHC.
Michelle Savoie is also an Associate Professor of Practical Training at the Faculty of Pharmacy, Université de Montréal and CEO, Consilio Manuque. Until July 2015, she was also CEO of Montréal InVivo. Mrs. Savoie has over 30 years of experience in the life sciences and pharmaceutical sector. She has held strategic positions at Schering Canada, Eli Lilly Canada and Bristol-Myers Squibb and participated in several boards including those of the Quebec Network for Personalized Healthcare (PHC), Montréal InVivo and Personalized Medicine Partnership for Cancer. She currently participated on the NEOMED Institute’s and the International Congress on PHC’s boards as well as on the Fonds de solidarité FTQ – New Economy Investment Committee. She was actively involved in the creation of the Quebec Consortium for Drug Discovery, the Quebec PHC Strategy, NEOMED and the early phase clinical research initiatives. A biochemist by training, she also completed an MBA, a Masters in Public Health, a PhD in biomedical sciences, a Masters in Law and Health policy and the Directors Education Program of the Institute of Corporate Directors.
Génome Québec and the Quebec Network for Personalized Health Care (QNPHC) have signed an agreement with Health Education England (HEE) ), who works across England to deliver high-quality education and training for the health and health care workforce.
This international partnership provides Québec with access to the recognized expertise of the United Kingdom, a pioneer in the development of training and education tools in the area of genomics and precision medicine. As part of this agreement, Génome Québec and the QNPHC have obtained translation and distribution rights for a French adaptation of their introductory online course in genomics pertaining to its current impact in clinical practice and its influence on the future of health care.
You can find the original version of this online training on the Health Education England Website.
Personalized Health Care
THE 4PS OF PERSONALIZED HEALTH CARE Predictive: Identification of individual risks of developing certain diseases based on the person’s genetic profile and other personal information Preventive: Methods …Read More
A focal point on PHC
The Quebec Network for Personalized Healthcare (QNPHC) is taking part in what can rightfully be called a revolution in healthcare management by providing a focal point and …Read More